Anticancer mechanisms of cannabinoids

Current Oncology

Volumn 23, Issue , 2016, Pages S23-S32

  Velasco, G ^a,b,c   Sanchez C ^a,d   Guzman M ^a,b,e  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d Instituto de Investigación Hospital 12 de Octubre ^*  (Spain)

^e INSTITUTO RAMÓN Y CAJAL DE INVESTIGACIÓN SANITARIA IRYCIS   (Spain)

Author keywords

Angiogenesis; Apoptosis; Autophagy; Cannabinoids; Cell proliferation; Cell signalling; Combination therapy

Indexed keywords

CANNABIDIOL; CANNABINOID; CANNABINOID RECEPTOR AGONIST; DRONABINOL; ENDOCANNABINOID; GEMCITABINE; TEMOZOLOMIDE;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOPHAGY; CANCER COMBINATION CHEMOTHERAPY; CELL INVASION; CELL PROLIFERATION; CELLULAR IMMUNITY; CONVULSION; COORDINATION DISORDER; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; GLIOBLASTOMA; GLIOMA; HUMAN; METASTASIS; NEOPLASM; NONHUMAN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR RESISTANCE;

EID: 84961674911     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.23.3080     Document Type: Review

References (96)

1. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964;86:1646-7.
2. Pertwee RG. The diverse cb1 and cb2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 2008;153:199-215.
3. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258:1946-9.
4. Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995;50:83-90.
5. Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995;215:89-97.
6. Pertwee RG, Howlett AC, Abood ME, et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond cb1 and cb2. Pharmacol Rev 2010;62:588-631.
7. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cdna. Nature 1990;346:561-4.
8. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61-5.
9. Fernandez-Ruiz J, Romero J, Velasco G, Tolon R, Ramos J, Guzman M. Cannabinoid cb2 receptor: a new target for controlling neural cell survival? Trends Pharmacol Sci 2007;28:39-45.
10. Atwood BK, Mackie K. cb2: a cannabinoid receptor with an identity crisis. Br J Pharmacol 2010;160:467-79.
11. Guzman M, Duarte MJ, Blazquez C, et al. A pilot clinical study of delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer 2006;95:197-203.
12. Sarfaraz S, Adhami VM, Syed DN, Afaq F, Mukhtar H. Cannabinoids for cancer treatment: progress and promise. Cancer Res 2008;68:339-42.
13. Katona I, Freund TF. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med 2008;14:923-30.
14. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006;58:389-462.
15. Pertwee RG. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 2009;156:397-411.
16. Guzman M. Cannabinoids: potential anticancer agents. Nat Rev Cancer 2003;3:745-55.
17. Velasco G, Sanchez C, Guzman M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer 2012;12:436-44.
18. Cudaback E, Marrs W, Moeller T, Stella N. The expression level of cb1 and cb2 receptors determines their efficacy at inducing apoptosis in astrocytomas. PloS One 2010;5:e8702.
19. Hart S, Fischer OM, Ullrich A. Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (tace/adam17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res 2004;64:1943-50.
20. McKallip RJ, Nagarkatti M, Nagarkatti PS. Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J Immunol 2005;174:3281-9.
21. Zhu LX, Sharma S, Stolina M, et al. Delta-9-tetrahydrocannabinol inhibits antitumour immunity by a cb2 receptormediated, cytokine-dependent pathway. J Immunol 2000;165:373-80.
22. Malfitano AM, Ciaglia E, Gangemi G, Gazzerro P, Laezza C, Bifulco M. Update on the endocannabinoid system as an anticancer target. Expert Opin Ther Targets 2011;15:297-308.
23. Sanchez C, de Ceballos ML, Gomez del Pulgar T, et al. Inhibition of glioma growth in vivo by selective activation of the cb2 cannabinoid receptor. Cancer Res 2001;61:5784-9.
24. Caffarel MM, Sarrio D, Palacios J, Guzman M, Sanchez C. Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res 2006;66:6615-21.
25. Nomura DK, Long JZ, Niessen S, Hoover HS, Ng SW, Cravatt BF. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 2010;140:49-61.
26. Thors L, Bergh A, Persson E, et al. Fatty acid amide hydrolase in prostate cancer: association with disease severity and outcome, cb1 receptor expression and regulation by il-4. PLoS One 2010;5:e12275.
27. Zheng D, Bode AM, Zhao Q, et al. The cannabinoid receptors are required for ultraviolet-induced inflammation and skin cancer development. Cancer Res 2008;68:3992-8.
28. Joosten M, Valk PJ, Jorda MA, et al. Leukemic predisposition of pSca-1/Cb2 transgenic mice. Exp Hematol 2002;30:142-9.
29. Perez-Gomez E, Andradas C, Blasco-Benito S, et al. Role of cannabinoid receptor cb2 in her2 pro-oncogenic signaling in breast cancer. J Natl Cancer Inst 2015;107:djv077.
30. Wang D, Wang H, Ning W, Backlund MG, Dey SK, DuBois RN. Loss of cannabinoid receptor 1 accelerates intestinal tumor growth. Cancer Res 2008;68:6468-76.
31. Izzo AA, Aviello G, Petrosino S, et al. Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon. J Mol Med (Berl) 2008;86:89-98.
32. Blazquez C, Gonzalez-Feria L, Alvarez L, Haro A, Casanova ML, Guzman M. Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res 2004;64:5617-23.
33. Galve-Roperh I, Sanchez C, Cortes ML, Gómez del Pulgar T, Izquierdo M, Guzman M. Antitumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 2000;6:313-19.
34. Gomez del Pulgar T, Velasco G, Sanchez C, Haro A, Guzman M. De novo-synthesized ceramide is involved in cannabinoidinduced apoptosis. Biochem J 2002;363:183-8.
35. Carracedo A, Lorente M, Egia A, et al. The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cancer Cell 2006;9:301-12.
36. Encinar JA, Mallo GV, Mizyrycki C, et al. Human p8 is a hmg-i/y-like protein with dna binding activity enhanced by phosphorylation. J Biol Chem 2001;276:2742-51.
37. Salazar M, Carracedo A, Salanueva IJ, et al. Cannabinoid action induces autophagy-mediated cell death through stimulation of er stress in human glioma cells. J Clin Invest 2009;119:1359-72.
38. Du K, Herzig S, Kulkarni RN, Montminy M. trb3: a tribbles homolog that inhibits Akt/pkb activation by insulin in liver. Science 2003;300:1574-7.
39. Verfaillie T, Salazar M, Velasco G, Agostinis P. Linking er stress to autophagy: potential implications for cancer therapy. Int J Cell Biol 2010;2010:930509.
40. Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature 2008;451:1069-75.
41. Eisenberg-Lerner A, Bialik S, Simon HU, Kimchi A. Life and death partners: apoptosis, autophagy and the cross-talk between them. Cell Death Differ 2009;16:966-75.
42. Galluzzi L, Pietrocola F, Bravo-San Pedro JM, et al. Autophagy in malignant transformation and cancer progression. EMBO J 2015;34:856-80.
43. Vara D, Salazar M, Olea-Herrero N, Guzman M, Velasco G, Diaz-Laviada I. Antitumoral action of cannabinoids on hepatocellular carcinoma: role of ampk-dependent activation of autophagy. Cell Death Differ 2011;18:1099-111.
44. Armstrong JL, Hill DS, McKee CS, et al. Exploiting cannabinoid-induced cytotoxic autophagy to drive melanoma cell death. J Invest Dermatol 2015;135:1629-37.
45. Ellert-Miklaszewska A, Kaminska B, Konarska L. Cannabinoids down-regulate pi3k/Akt and Erk signalling pathways and activate proapoptotic function of Bad protein. Cell Signal 2005;17:25-37.
46. Blazquez C, Carracedo A, Barrado L, et al. Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J 2006;20:2633-5.
47. Caffarel MM, Moreno-Bueno G, Cerutti C, et al. JunD is involved in the antiproliferative effect of delta9-tetrahydrocannabinol on human breast cancer cells. Oncogene 2008;27:5033-44.
48. Carracedo A, Gironella M, Lorente M, et al. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res 2006;66:6748-55.
49. Salazar M, Lorente M, Garcia-Taboada E, et al. The pseudokinase tribbles homologue-3 plays a crucial role in cannabinoid anticancer action. Biochim Biophys Acta 2013;1831:1573-8.
50. Caffarel MM, Andradas C, Perez-Gomez E, Guzman M, Sanchez C. Cannabinoids: a new hope for breast cancer therapy? Cancer Treat Rev 2012;38:911-18.
51. Sarfaraz S, Afaq F, Adhami VM, Malik A, Mukhtar H. Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of erk1/2 leading to G1 cell cycle arrest. J Biol Chem 2006;281:39480-91.
52. Guindon J, Hohmann AG. The endocannabinoid system and cancer: therapeut ic implicat ion. Br J Pharmacol 2011;163:1447-63.
53. Galve-Roperh I, Aguado T, Palazuelos J, Guzman M. Mechanisms of control of neuron survival by the endocannabinoid system. Curr Pharm Des 2008;14:2279-88.
54. Casanova ML, Blazquez C, Martinez-Palacio J, et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 2003;111:43-50.
55. Chan PC, Sills RC, Braun AG, Haseman JK, Bucher JR. Toxicity and carcinogenicity of delta 9-tetrahydrocannabinol in Fischer rats and B6C3F1 mice. Fundam Appl Toxicol 1996;30:109-17.
56. Lorente M, Torres S, Salazar M, et al. Stimulation of the midkine/ alk axis renders glioma cells resistant to cannabinoid antitumoral action. Cell Death Differ 2011;18:959-73.
57. Ligresti A, Moriello AS, Starowicz K, et al. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther 2006;318:1375-87.
58. Massi P, Valenti M, Vaccani A, et al. 5-Lipoxygenase and anandamide hydrolase (faah) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. J Neurochem 2008;104:1091-100.
59. Shrivastava A, Kuzontkoski PM, Groopman JE, Prasad A. Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. Mol Cancer Ther 2011;10:1161-72.
60. Nabissi M, Morelli MB, Santoni M, Santoni G. Triggering of the trpv2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents. Carcinogenesis 2012;34:48-57.
61. Blazquez C, Casanova ML, Planas A, et al. Inhibition of tumor angiogenesis by cannabinoids. FASEB J 2003;17:529-31.
62. Portella G, Laezza C, Laccetti P, De Petrocellis L, Di Marzo V, Bifulco M. Inhibitory effects of cannabinoid cb1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J 2003;17:1771-3.
63. Pisanti S, Borselli C, Oliviero O, Laezza C, Gazzerro P, Bifulco M. Antiangiogenic activity of the endocannabinoid anandamide: correlation to its tumor-suppressor efficacy. J Cell Physiol 2007;211:495-503.
64. Blazquez C, Salazar M, Carracedo A, et al. Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression. Cancer Res 2008;68:1945-52.
65. Grimaldi C, Pisanti S, Laezza C, et al. Anandamide inhibits adhesion and migration of breast cancer cells. Exp Cell Res 2006;312:363-73.
66. Qamri Z, Preet A, Nasser MW, et al. Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. Mol Cancer Ther 2009;8:3117-29.
67. Preet A, Ganju RK, Groopman JE. Delta9-tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. Oncogene 2008;27:339-46.
68. Ramer R, Hinz B. Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1. J Natl Cancer Inst 2008;100:59-69.
69. McAllister SD, Murase R, Christian RT, et al. Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Res Treat 2011;129:37-47.
70. Soroceanu L, Murase R, Limbad C, et al. Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target. Cancer Res 2012;73:1559-69.
71. Newton CA, Chou PJ, Perkins I, Klein TW. cb1 and cb2 cannabinoid receptors mediate different aspects of delta-9-tetrahydrocannabinol (thc)-induced T helper cell shift following immune activation by Legionella pneumophila infection. J Neuroimmune Pharmacol 2009;4:92-102.
72. Lu T, Newton C, Perkins I, Friedman H, Klein TW. Cannabinoid treatment suppresses the T-helper cell-polarizing function of mouse dendritic cells stimulated with Legionella pneumophila infection. J Pharmacol Exp Ther 2006;319:269-76.
73. Steffens S, Veillard NR, Arnaud C, et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 2005;434:782-6. [Erratum in: Nature 2005;435:528]
74. Hegde VL, Nagarkatti M, Nagarkatti PS. Cannabinoid receptor activation leads to massive mobilization of myeloid-derived suppressor cells with potent immunosuppressive properties. Eur J Immunol 2010;40:3358-71.
75. Burstein SH, Zurier RB. Cannabinoids, endocannabinoids, and related analogs in inflammation. AAPS J 2009;11:109-19.
76. Liu WM, Fowler DW, Dalgleish AG. Cannabis-derived substances in cancer therapy—an emerging anti-inflammatory role for the cannabinoids. Curr Clin Pharmacol 2010;5:281-7.
77. Mirkin BL, Clark S, Zheng X, et al. Identification of midkine as a mediator for intercellular transfer of drug resistance. Oncogene 2005;24:4965-74.
78. Kadomatsu K. The midkine family in cancer, inflammation and neural development. Nagoya J Med Sci 2005;67:71-82.
79. Palmer RH, Vernersson E, Grabbe C, Hallberg B. Anaplastic lymphoma kinase: signalling in development and disease. Biochem J 2009;420:345-61.
80. Lonardi S, Tosoni A, Brandes AA. Adjuvant chemotherapy in the treatment of high grade gliomas. Cancer Treat Rev 2005;31:79-89.
81. Nieder C, Adam M, Molls M, Grosu AL. Therapeutic options for recurrent high-grade glioma in adult patients: recent advances. Crit Rev Oncol Hematol 2006;60:181-93.
82. Purow B, Schiff D. Advances in the genetics of glioblastoma: are we reaching critical mass? Nat Rev Neurol 2009;5:419-26.
83. Lorente M, Carracedo A, Torres S, et al. Amphiregulin is a factor for resistance of glioma cells to cannabinoid-induced apoptosis. Glia 2009;57:1374-85.
84. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
85. Torres S, Lorente M, Rodriguez-Fornes F, et al. A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther 2011;10:90-103.
86. de Bono JS, Ashworth A. Translating cancer research into targeted therapeutics. Nature 2010;467:543-9.
87. Grande E, Bolos MV, Arriola E. Targeting oncogenic alk: a promising strategy for cancer treatment. Mol Cancer Ther 2011;10:569-79.
88. Donadelli M, Dando I, Zaniboni T, et al. Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ros-mediated mechanism. Cell Death Dis 2011;2:e152.
89. Miyato H, Kitayama J, Yamashita H, et al. Pharmacological synergism between cannabinoids and paclitaxel in gastric cancer cell lines. J Surg Res 2009;155:40-7.
90. Gustafsson SB, Lindgren T, Jonsson M, Jacobsson SO. Cannabinoid receptor-independent cytotoxic effects of cannabinoids in human colorectal carcinoma cells: synergism with 5-fluorouracil. Cancer Chemother Pharmacol 2009;63:691-701.
91. Massi P, Vaccani A, Bianchessi S, Costa B, Macchi P, Parolaro D. The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. Cell Mol Life Sci 2006;63:2057-66.
92. McAllister SD, Christian RT, Horowitz MP, Garcia A, Desprez PY. Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Mol Cancer Ther 2007;6:2921-7.
93. Marcu JP, Christian RT, Lau D, et al. Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival. Mol Cancer Ther 2010;9:180-9.
94. Scott KA, Dalgleish AG, Liu WM. The combination of cannabidiol and Delta9-tetrahydrocannabinol enhances the anticancer effects of radiation in an orthotopic murine glioma model. Mol Cancer Ther 2014;13:2955-67.
95. Bifulco M, Laezza C, Portella G, et al. Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. FASEB J 2001;15:2745-7.
96. Ligresti A, Bisogno T, Matias I, et al. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 2003;125:677-87.